Nov 21, 2024 | Bariatric surgery, GLP-1s, MedBen Rx, Wegovy, Weight loss, Weight loss drugs, Zepbound
Bariatric surgeries to treat obesity dropped 25.6% from 2022 to 2023, while prescriptions for GLP-1 drugs more than doubled during that period, according to a new study of privately insured Americans with obesity. However, those who opt for the surgery are seeing...
Nov 11, 2024 | Flexible spending accounts (FSAs), Genomics, MedBen Rx, Nutrigenomics, Pharmacogenomics
Genomic testing is revolutionizing precision medicine, offering unprecedented insights into how your body interacts with medications and nutrients. MedBen Rx offers pharmacogenomic and nutrigenomic tests that can help optimize your employees’ health care and...
Oct 29, 2024 | Alternative Reimbursement Strategies, Chronic conditions, Client Report, Cost projections, Cost Savings, Direct-to-Employer Contracting, Drug costs, Fair market reimbursement, Forensic claims review, Health care costs, High-cost claims, MedBen Rx, MedBen WellLiving, Prescription, Rx Costs, Transparency, Trend, Wellness
Health care costs in the United States are projected to see their steepest rise in over a decade during 2025, with multiple industry analyses forecasting increases between 7% and 8% year-over-year (see table below). However, MedBen offers solutions that directly...
Jul 5, 2024 | Biosimilars, Cost Savings, Humira, MedBen Rx, News, Rx Costs, Savings
The Food and Drug Administration is considering a change to its biosimilar policy that would greatly speed up their approval process – which, if enacted, would be a big win for MedBen Rx clients who are already reducing their prescription drug spend through...
Jun 10, 2024 | Affordable Care Act, Caroline Fraker, MedBen Rx, Obesity, Wegovy, Weight loss, Weight loss drugs, Zepbound
While most health plans do not currently cover obesity medications like Wegovy and Zepbound – and MedBen Rx recommends clients continue not to do so – constant media coverage means the calls to do so will only grow. Therefore, employers are increasingly considering...
May 13, 2024 | Diabetes, Kurt Harden, MedBen Rx, MedBen University, Mounjaro, Ozempic, Wegovy, Weight loss, Zepbound
At recent MedBen University roundtables, MedBen President & CEO Kurt Harden examined how the growing public awareness of two diabetes drugs with a desirable side effect – significant weight loss – means that these $1,000-per-month medications are not always being...
